CG Oncology Raises $120 Million in Oversubscribed Series E …
Our lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types … See more
OFF
CG Oncology Raises $120 Million In Oversubscribed Series E …
4 weeks from now
Our lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types … See more
cgoncology.com
OFF
CG Oncology Raises $120 Million In Oversubscribed Series E …
4 weeks from now
CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline ... CG Oncology Announces First Patient Dosed in PIVOT …
sironacap.com
OFF
CG Oncology Raises $120 Million In Oversubscribed Series E …
4 weeks from now
IRVINE, Calif., November 15, 2022--CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline
yahoo.com
OFF
CG Oncology Raises $120 Million In Oversubscribed Series E
4 weeks from now
Nov 15, 2022 · CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced the close of an …
biospace.com
OFF
CG Oncology Raises $120 Million In Oversubscribed Series E
4 weeks from now
IRVINE, Calif., November 15, 2022 – CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced …
malinplc.com
OFF
CG Oncology Completes $120M Series E - Vcnewsdaily.com
4 weeks from now
Nov 15, 2022 · CG Oncology, an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced the close of an …
vcnewsdaily.com
OFF
Malin : CG Oncology Raises $120 Million In Oversubscribed Series …
4 weeks from now
Nov 15, 2022 · - Brian Liu, M.D., Principal, Longitude Capital to join board of directors - IRVINE, Calif., November 15, 2022 - CG Oncology, Inc., an oncolytic immunotherapy company focused …
marketscreener.com
OFF
Latham & Watkins Advises CG Oncology In US$120 Million Series …
4 weeks from now
Nov 30, 2022 · CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, has announced the close of an …
lw.com
OFF
Series E - CG Oncology - 2022-11-15 - Crunchbase
4 weeks from now
Nov 15, 2022 · FinSMEs — CG Oncology Raises $120M in Series E Financing News • Nov 15, 2022 cgoncology.com — CG Oncology Raises $120 Million in Oversubscribed Series E …
crunchbase.com
OFF
CG Oncology Raises $120M For Research - Orange County …
4 weeks from now
Nov 21, 2022 · CG Oncology Inc. has spent more than a decade trying to find solutions to bladder cancer. Investors believe the Irvinebased oncology researcher is getting closer. The …
pressreader.com
OFF
CG Oncology Raises $120M In Series E Financing - FinSMEs
4 weeks from now
Nov 17, 2022 · CG Oncology, an Irvine, CA-based oncolytic immunotherapy company, raised $120M in Series E funding.. The round was co-led by ORI Capital, Longitude Capital and …
finsmes.com
OFF
CG Oncology Raises $105M For Bladder Cancer Work
4 weeks from now
Aug 14, 2023 · The newest funding round follows a Series E round for the immunotherapy firm in late 2022 that raised $120 million and was also oversubscribed. CG Oncology now has …
ocbj.com
OFF
CG Oncology Announces $105 Million Oversubscribed Crossover …
4 weeks from now
Aug 2, 2023 · – Co-led by new investors Foresite Capital and TCGX – – Proceeds to advance late-stage clinical programs in bladder cancer towards FDA approval – August 2, 2023, 8:00 …
cgoncology.com
OFF
CG Oncology Raises $120 Million In Oversubscribed Series E …
4 weeks from now
IRVINE, Calif., November 15, 2022-- CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced …
vcaonline.com
OFF
CG Oncology Raises $120 Million In Oversubscribed Series E …
4 weeks from now
Nov 15, 2022 · CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced the close of an …
financialcontent.com
OFF
CG Oncology Raises $120 Million In Oversubscribed Series E …
4 weeks from now
On November 15, 2022 CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, reported the close of an …
1stoncology.com
FAQs about CG Oncology Raises $120 Million in Oversubscribed Series E … Coupon?
Who owns CG oncology?
Who is CG oncology?
Is CG oncology a risky company?
Does cg0070 work with nivolumab?
Is cg0070 a first-line treatment for BCG-nave and intermediate-risk NMIBC?
Does cg0070 work in patients with bladder cancer unresponsive to BCG?
Install CouponFollow Extension on Chrome
Install the CouponFollow extension to search for discount codes when shopping the fastest!
Install CouponFollow Chrome Extension
Listing Store by Characters
